EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F08%3A4081" target="_blank" >RIV/00064203:_____/08:4081 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/08:4081
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Original language description
To determine whether adding cetuximab to irinotecan prolongs survival in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine and oxaliplatin.
Czech name
EPIC: Klinická studie fáze III Cetuximab plus Irinotecan po selhání Fluoropyrimidinů a Oxaliplatiny u pacientů s metastaickým kolorektálním karcinomem
Czech description
EPIC: Klinická studie fáze III Cetuximab plus Irinotecan po selhání Fluoropyrimidinů a Oxaliplatiny u pacientů s metastaickým kolorektálním karcinomem.
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2008
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
—
Volume of the periodical
26
Issue of the periodical within the volume
14
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
—
UT code for WoS article
000255746600015
EID of the result in the Scopus database
—